Hikma Pharmaceuticals PLC · LSE:HIK
Hikma Pharmaceuticals — Merger or Acquisition (May 2014)
11 slides from Hikma Pharmaceuticals's merger presentation, May 28, 2014
Slide 1: Positioning Hikma as a future leader in US generic injectables
Hikma Pharmaceuticals PLC Positioning Hikma as a future leader in US generic injectables
Slide 2: Disclaimer
► This document, which has been issued by Hikma Pharmaceuticals PLC (the “Company”), comprises the written materials/slides for a presentation. This document and its contents are confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or publis
Slide 3: A transformational deal, supporting our strategy to be a leading generic injectables company
A transformational deal, supporting our strategy to be a leading generic injectables company ► Acquiring substantially all of the assets of Bedford Laboratories (“Bedford”) from Ben Venue Laboratories, Inc., a member of the Boehringer Ingelheim Group of Companies, for a total consideration of up to
Slide 4: Hikma is focused on building a leading position in the large and fast growing US generic injectables market
Hikma is focused on building a leading position in the large and fast growing US generic injectables market US injectables market sales by value ($ billion)1 ► Global generic injectables market is estimated to exceed 100 Generic 2008-2013 CAGR: 19% $12 billion, with the US accounting for around $7.6
Slide 5: Creating the broadest portfolio of generic injectable products in the US
Creating the broadest portfolio of generic injectable products in the US US generic injectable suppliers – products marketed in the US in 20131 ► Bedford has the third largest portfolio of generic injectable products in the US 147 ► Bedford is currently marketing its third party products 84 and only
Slide 6: Bedford strengthens Hikma's platform for growth in US injectables
Bedford strengthens Hikma’s platform for growth in US injectables ► Acquiring a large portfolio of 84 products Bedford Laboratories – Acquiring 82 of Bedford’s own products and 2 products marketed under third party licenses – Large number of niche, differentiated products, including sizeable lyophil
Slide 7: Bedford brings a complementary portfolio across broad range of therapeutic categories
Bedford brings a complementary portfolio across broad range of therapeutic categories, including a number of differentiated products ► Acquiring 82 of Bedford’s own products ► Hikma expects to re-launch an initial tranche of around 20 products between 2015 and 2017 ► Prioritisation based on strength
Slide 8: Bedford's R&D and business development pipeline enhance growth opportunities
Bedford’s R&D and business development pipeline enhance growth opportunities R&D pipeline Business development opportunities ► Strong R&D team with track record of developing ► Team includes people focused on external product licensing differentiated products and co-development partnerships ► Curren
Slide 9: Hikma's strong manufacturing and technical expertise will facilitate a smooth and effective integration process
Hikma’s strong manufacturing and technical expertise will facilitate a smooth and effective integration process ► Targeting to tech-transfer an initial tranche of around 20 of the acquired products to our manufacturing facilities in Germany, Portugal and the US ► Utilisation of acquired raw material
Slide 10: Expected to be strongly accretive to EPS from 2016 onwards following tech transfer
Expected to be strongly accretive to EPS from 2016 onwards following tech transfer of products to Hikma’s own facilities ► Limited revenue in 2014 and 2015 while products are being transferred to Hikma’s facilities ► Revenue is expected to significantly increase from 2016 onwards, driven by: Impact
Slide 11: Positioning Hikma as a future leader in US generic injectables
Positioning Hikma as a future leader in US generic injectables ► Creates the broadest portfolio of generic injectable products in the US ► Large, differentiated portfolio, including a sizeable number of oncology products, strengthens our market position ► Experienced R&D and business development tea
Hikma Pharmaceuticals — Merger or Acquisition (May 2014) on 6ix